X. Long Zheng, MD, PhD, details the typical healthcare costs for acquired TTP, the treatment options available to patients, and the goals of the healthcare provider. X. Long Zheng, MD, PhD: What does ...

Immune thrombotic thrombocytopenic purpura (TTP) can be treated safely and effectively with caplacizumab. Cases of immune thrombotic thrombocytopenic purpura (iTTP) that are refractory to plasma ...

In a new study by Yale Cancer Center (YCC) researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care ...

The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

London, UK - Researchers have made a breakthrough in identifying the molecular pathogenesis of thrombotic thrombocytopenic purpura (TTP). They have proven that disruption of an enzyme that cleaves the ...

St. Louis, Jan. 21, 2003 -- Treatment with two medications that suppress the immune system, rituximab and cyclophosphamide, appears to have cured one woman of an otherwise untreatable case of the ...

It was a rare, aggressive blood disorder. Large teaching hospitals like the University of Tennessee Medical Center saw two or three cases a year of potentially deadly thrombotic thrombocytopenic ...

A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC). This is an ASCO Meeting Abstract from the ...